AXIM BIOTECHNOLOGIES, INC.
Form 8-K
May 17, 2017

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): May 15, 2017

AXIM BIOTECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

Nevada	000-54296	27-4092986
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

5 Rockefeller Plaza, 20th Floor

New York, NY	10022
(Address of principal executive offices)	(Zip Code)

(212) 751-0001
(Registrant s telephone number, including area code)

(Former name if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure

On May 15, 2017, AXIM Biotechnologies, Inc. issued a press release which announced that information on the company s Bioavailability Study on Dronabinol in a controlled-release, functional chewing gum form was now available on National Institutes of Health website https://clinicaltrials.gov/ct2/show/NCT03098940?term=axim&rank=1 officially titled A Two Part, Open Label, Randomized, Four Period Cross-over Study to Compare the Bioavailability of Two Different Dronabinol Formulations in Healthy Male and Female Volunteers. The Company believes that the clinical study will pave the scientific foundation for AXIM and its controlled-substance API partner to co-develop a dronabinol-based functional, controlled-release chewing gum product. The new dronabinol chewing gum product will be bioequivalent to Marinol®, and will be used to help treat patients with chemotherapy induced nausea and vomiting and AIDS patients experiencing appetite and weight loss.

The information set forth under this Item 7.01, including Exhibit 99.1, is being furnished and, as a result, such information shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of such Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 - Financial Statements and Exhibits

(d) Exhibits

99.1 Press Release

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AXIM BIOTECHNOLOGIES, INC.

Dated: May 15, 2017	By:	*/s/ Dr. George E. Anastassov* Name: Dr. George E. Anastassov Chief Executive Officer